NCT00269113View on ClinicalTrials.gov

A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

September 30, 1998

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

rituximab [MabThera/Rituxan]

375mg/m2 iv monthly for 8 cycles

DRUG

Standard chemotherapy

As prescribed

Trial Locations (33)

12203

Berlin

13122

Berlin

14467

Potsdam

15236

Frankfurt (Oder)

17036

Neubrandenburg

17475

Greifswald

18055

Rostock

18057

Rostock

18273

Güstrow

18435

Stralsund

19049

Schwerin

35043

Marburg

39120

Magdeburg

39130

Magdeburg

44791

Bochum

48249

Dülmen

53127

Bonn

54290

Trier

98544

Zella-Mehlis

99089

Erfurt

99734

Nordhausen

04552

Borna

09113

Chemnitz

03046

Cottbus

01067

Dresden

01307

Dresden

06110

Halle

06120

Halle

07743

Jena

07747

Jena

04103

Leipzig

04315

Leipzig

01589

Riesa

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00269113 - A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter